 Polycystic Kidney, Autosomal Dominant
"Polycystic Kidney, Autosomal Dominant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.
| Descriptor ID |
D016891
|
| MeSH Number(s) |
C12.777.419.403.875.500 C13.351.968.419.403.875.500
|
| Concept/Terms |
Polycystic Kidney, Autosomal Dominant- Polycystic Kidney, Autosomal Dominant
- Adult Polycystic Kidney Disease
- Kidney, Polycystic, Autosomal Dominant
- ADPKD
- Polycystic Kidney Disease, Autosomal Dominant
- Autosomal Dominant Polycystic Kidney
|
Below are MeSH descriptors whose meaning is more general than "Polycystic Kidney, Autosomal Dominant".
Below are MeSH descriptors whose meaning is more specific than "Polycystic Kidney, Autosomal Dominant".
This graph shows the total number of publications written about "Polycystic Kidney, Autosomal Dominant" by people in this website by year, and whether "Polycystic Kidney, Autosomal Dominant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 6 | 1 | 7 | | 2004 | 1 | 0 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 5 | 0 | 5 | | 2007 | 2 | 0 | 2 | | 2008 | 5 | 0 | 5 | | 2009 | 4 | 0 | 4 | | 2010 | 4 | 0 | 4 | | 2011 | 4 | 0 | 4 | | 2012 | 4 | 0 | 4 | | 2013 | 6 | 0 | 6 | | 2014 | 7 | 0 | 7 | | 2015 | 7 | 0 | 7 | | 2016 | 13 | 0 | 13 | | 2017 | 17 | 0 | 17 | | 2018 | 7 | 0 | 7 | | 2019 | 4 | 0 | 4 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Polycystic Kidney, Autosomal Dominant" by people in Profiles.
-
Cho Y, Rangan G, Logeman C, Ryu H, Sautenet B, Perrone RD, Nadeau-Fredette AC, Mustafa RA, Htay H, Chonchol M, Harris T, Gutman T, Craig JC, Ong ACM, Chapman A, Ahn C, Coolican H, Kao JT, Gansevoort RT, Torres V, Pei Y, Johnson DW, Viecelli AK, Teixeira-Pinto A, Howell M, Ju A, Manera KE, Tong A. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Am J Kidney Dis. 2020 09; 76(3):361-373.
-
Sautenet B, Cho Y, Gutman T, Rangan G, Ong A, Chapman AB, Ahn C, Coolican H, Tze-Wah Kao J, Fowler K, Gansevoort RT, Geneste C, Perrone RD, Harris T, Torres VE, Pei Y, Craig JC, Tong A. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Am J Kidney Dis. 2020 08; 76(2):213-223.
-
Bae KT, Zhou W, Shen C, Landsittel DP, Wu Z, Tao C, Chapman AB, Torres VE, Yu ASL, Mrug M, Bennett WM, Harris PC. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833.
-
Cho Y, Sautenet B, Gutman T, Rangan G, Craig JC, Ong AC, Chapman A, Ahn C, Coolican H, Kao JT, Gansevoort R, Perrone RD, Harris T, Torres V, Pei Y, Kerr PG, Ryan J, Johnson DW, Viecelli AK, Geneste C, Kim H, Kim Y, Oh YK, Teixeira-Pinto A, Logeman C, Howell M, Ju A, Manera KE, Tong A. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology (Carlton). 2019 Dec; 24(12):1214-1224.
-
Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
-
Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019 05; 95(5):1253-1261.
-
McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, Rahbari-Oskoui FF, Bae KT, Landsittel DP, Bennett WM, Yu ASL, Mahnken JD. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol. 2018 12 27; 19(1):378.
-
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
-
Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
-
Rahbari-Oskoui FF, Chapman AB. Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease. Am J Nephrol. 2018; 47(4):228-230.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|